Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to $382.5 million.

  • Anaptysbio's Total Liabilities fell 648.75% to $382.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.5 million, marking a year-over-year decrease of 648.75%. This contributed to the annual value of $413.0 million for FY2024, which is 1336.31% up from last year.
  • As of Q3 2025, Anaptysbio's Total Liabilities stood at $382.5 million, which was down 648.75% from $380.0 million recorded in Q2 2025.
  • Anaptysbio's 5-year Total Liabilities high stood at $417.5 million for Q2 2024, and its period low was $14.5 million during Q1 2021.
  • For the 5-year period, Anaptysbio's Total Liabilities averaged around $309.2 million, with its median value being $360.7 million (2023).
  • In the last 5 years, Anaptysbio's Total Liabilities tumbled by 3884.41% in 2021 and then skyrocketed by 193401.73% in 2022.
  • Anaptysbio's Total Liabilities (Quarter) stood at $286.6 million in 2021, then rose by 21.5% to $348.3 million in 2022, then grew by 4.6% to $364.3 million in 2023, then grew by 13.36% to $413.0 million in 2024, then decreased by 7.37% to $382.5 million in 2025.
  • Its Total Liabilities was $382.5 million in Q3 2025, compared to $380.0 million in Q2 2025 and $388.0 million in Q1 2025.